UroGen Pharma Announces Pricing Of Public Offering Of Shares And Pre-Funded Warrants

(RTTNews) - UroGen Pharma Ltd. (URGN) announced the pricing of an underwritten public offering of 5 million ordinary shares at a price to the public of $17.50 per ordinary share, and, to certain investors in lieu of issuing ordinary shares, pre-funded warrants to purchase 1.14 million ordinary shares at a purchase price of $17.499 per pre-funded warrant, which equals the public offering price per ordinary share less the $0.001 per share exercise price for each pre-funded warrant.

The company expects gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, to be approximately $107.5 million.

In addition, UroGen granted the underwriters a 30-day option to purchase up to an additional 921,428 ordinary shares at the public offering price, less underwriting discounts and commissions.

The offering is expected to close on June 20, 2024.